WO2001003672A1 - Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif - Google Patents

Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif Download PDF

Info

Publication number
WO2001003672A1
WO2001003672A1 PCT/FR2000/001855 FR0001855W WO0103672A1 WO 2001003672 A1 WO2001003672 A1 WO 2001003672A1 FR 0001855 W FR0001855 W FR 0001855W WO 0103672 A1 WO0103672 A1 WO 0103672A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating
agent
coated granules
mixture
granules according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2000/001855
Other languages
English (en)
French (fr)
Inventor
Noureddine Nouri
Jean-Marc Zuccarelli
Charles Chauveau
Etienne Bruna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Laboratories Prographarm SA
Original Assignee
Ethypharm SAS
Laboratories Prographarm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU59936/00A priority Critical patent/AU760006B2/en
Priority to EP00946045A priority patent/EP1194125B1/fr
Priority to SK1939-2001A priority patent/SK287322B6/sk
Priority to HU0202062A priority patent/HU229568B1/hu
Priority to JP2001508953A priority patent/JP4749639B2/ja
Priority to PL354257A priority patent/PL201782B1/pl
Priority to EA200200136A priority patent/EA003161B1/ru
Priority to CA2375600A priority patent/CA2375600C/fr
Priority to DZ003257A priority patent/DZ3257A1/fr
Priority to DK00946045T priority patent/DK1194125T3/da
Priority to NZ516594A priority patent/NZ516594A/en
Application filed by Ethypharm SAS, Laboratories Prographarm SA filed Critical Ethypharm SAS
Priority to BR0012250-5A priority patent/BR0012250A/pt
Priority to MXPA01013354A priority patent/MXPA01013354A/es
Priority to IL14721200A priority patent/IL147212A0/xx
Priority to DE60034565T priority patent/DE60034565T2/de
Priority to HK03101347.5A priority patent/HK1049119B/zh
Publication of WO2001003672A1 publication Critical patent/WO2001003672A1/fr
Priority to IL147212A priority patent/IL147212A/en
Priority to NO20016308A priority patent/NO331256B1/no
Priority to US10/041,389 priority patent/US6660382B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer

Definitions

  • immediate release of active principle means that the release kinetics of the active molecule are not substantially modified by the formulation and / or by the parameters of the manufacturing process. (see in particular document of the European Medicines Agency "note for guidance on modified release oral and transdermal dosage forms" of 04/22/1998). Consequently, the dissolution profile of the active principle depends essentially on its intrinsic properties.
  • pH polymers depending on their domain of solubility, can cause a delayed release of the active principle until in the distal part of the intestine.
  • a coating is incompatible with an immediate release of the active principle.
  • document WO 98/47493 describes a pharmaceutical composition in the form of granules coated with a polymeric film of the acrylic type, which, as expressly indicated, results in delayed release of the active principle.
  • the objective of the invention is to propose a process for manufacturing coated granules, the taste of the active ingredient of which is masked, and the release of the active ingredient of which is immediate, regardless of the nature of the coating polymer.
  • the constituents of a powder are dry mixed comprising at least the active principle and a granular disintegrating agent; • the powder obtained is then granulated, in the presence of a mixture of excipients comprising at least one binding agent capable of binding the particles together to obtain grains;
  • membrane disintegrating agent denotes an excipient capable of increasing the speed of disintegration of the coating layer of the granules, obtained at the end of the step. coating.
  • the method of the invention makes it possible to solve, surprisingly and unexpectedly, the two problems with the conflicting solutions which are those of obtaining the masking of the taste of the active principle by coating, while not delaying the solubilization of the active principle, however. , by integrating both at the granular level and at the membrane level, in addition to the presence respectively of a binding agent and of a coating agent, that of disintegrating agents (granular and membrane).
  • binding agent and the coating agent are chosen from the same group of compounds, they nevertheless differ from each other by their function as mentioned above.
  • cellulose polymers ethylcellulose, hydroxypropylcellulose (HPC), carboxymethylcellulose (CMC) and hydroxypropylmethylcellulose (HPMC) are advantageously chosen, alone or as a mixture.
  • acrylic polymers that will advantageously be chosen the ammonio-methacrylate copolymer (Eudragit ® RL or RS), the polyacrylate (Eudragit ® NE), the methacrylic acid copolymer (Eudragit ® L or S), Eudragit ® being a registered trademark by ROHM.
  • the binding agent is of the same nature as the coating agent.
  • sweetening agent it is possible to use aspartame, potassium acesulfam, sodium saccharinate, neohesperidin dihydrochalcone, monoamonium glycy ⁇ hizinate, sugars and derivatives, as well as polyols and derivatives, alone or as a mixture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Seasonings (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/FR2000/001855 1999-07-08 2000-06-30 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif Ceased WO2001003672A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
NZ516594A NZ516594A (en) 1999-07-08 2000-06-30 Process for manufacturing coated granules with masked taste and immediate release of the active principle
SK1939-2001A SK287322B6 (sk) 1999-07-08 2000-06-30 Spôsob výroby poťahovaných granúl s maskovanou chuťou a okamžitým uvoľňovaním účinnej zložky
HU0202062A HU229568B1 (hu) 1999-07-08 2000-06-30 Eljárás maszkírozott ízû és azonnali hatóanyag-leadású bevont szemcsék elõállítására
JP2001508953A JP4749639B2 (ja) 1999-07-08 2000-06-30 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法
PL354257A PL201782B1 (pl) 1999-07-08 2000-06-30 Sposób wytwarzania powlekanych granul o zamaskowanym smaku i niezwłocznie uwalniających składnik czynny, powlekana granula, szybko krusząca się wielocząstkowa tabletka oraz szybko rozpadająca się tabletka
EA200200136A EA003161B1 (ru) 1999-07-08 2000-06-30 Способ получения покрытых гранул со скрытым вкусом и немедленным высвобождением активного ингредиента
BR0012250-5A BR0012250A (pt) 1999-07-08 2000-06-30 Processo de fabricação de grânulos revestidos com gosto mascarado, e liberação imediata do princìpio ativo, grânulo revestido, comprimido multiparticulado de dissolução rápida e comprimido de hidrodispersibilidade rápida
EP00946045A EP1194125B1 (fr) 1999-07-08 2000-06-30 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
DK00946045T DK1194125T3 (da) 1999-07-08 2000-06-30 Fremgangsmåde til fremstilling af et overtrukket granulat med maskeret smag og umiddelbar frisætning af aktive stof
AU59936/00A AU760006B2 (en) 1999-07-08 2000-06-30 Method for making granules with masked taste and instant release of the active particle
DZ003257A DZ3257A1 (fr) 1999-07-08 2000-06-30 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
CA2375600A CA2375600C (fr) 1999-07-08 2000-06-30 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
MXPA01013354A MXPA01013354A (es) 1999-07-08 2000-06-30 Proceso para la fabricacion de granulos recubiertos con sabor oculto y liberacion inmediata del principio activo.
IL14721200A IL147212A0 (en) 1999-07-08 2000-06-30 A process for the manufacture of coated granules with masked taste
DE60034565T DE60034565T2 (de) 1999-07-08 2000-06-30 Verfahren zur herstellung eines umhüllten geschmackmaskierten granulats mit sofortiger wirkstofffreisetzung
HK03101347.5A HK1049119B (zh) 1999-07-08 2000-06-30 制备遮味的且活性物质即释的包衣颗粒的方法
IL147212A IL147212A (en) 1999-07-08 2001-12-20 Process to create coated kernels with camouflaged flavor
NO20016308A NO331256B1 (no) 1999-07-08 2001-12-21 Fremgangsmate for fremstilling av granuler med maskert smak og umiddelbar frigjoring av det aktive prinsipp
US10/041,389 US6660382B2 (en) 1999-07-08 2002-01-08 Process for manufacturing coated granules with masked taste and immediate release of the active principle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909047A FR2795962B1 (fr) 1999-07-08 1999-07-08 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
FR99/09047 1999-07-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/041,389 Continuation US6660382B2 (en) 1999-07-08 2002-01-08 Process for manufacturing coated granules with masked taste and immediate release of the active principle

Publications (1)

Publication Number Publication Date
WO2001003672A1 true WO2001003672A1 (fr) 2001-01-18

Family

ID=9548029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001855 Ceased WO2001003672A1 (fr) 1999-07-08 2000-06-30 Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif

Country Status (31)

Country Link
US (1) US6660382B2 (https=)
EP (1) EP1194125B1 (https=)
JP (1) JP4749639B2 (https=)
KR (1) KR100767928B1 (https=)
CN (1) CN1220485C (https=)
AT (1) ATE360412T1 (https=)
AU (1) AU760006B2 (https=)
BG (1) BG65615B1 (https=)
BR (1) BR0012250A (https=)
CA (1) CA2375600C (https=)
CY (1) CY1107695T1 (https=)
CZ (1) CZ300154B6 (https=)
DE (1) DE60034565T2 (https=)
DK (1) DK1194125T3 (https=)
DZ (1) DZ3257A1 (https=)
EA (1) EA003161B1 (https=)
ES (1) ES2284507T3 (https=)
FR (1) FR2795962B1 (https=)
HK (1) HK1049119B (https=)
HU (1) HU229568B1 (https=)
IL (2) IL147212A0 (https=)
MA (1) MA25426A1 (https=)
MX (1) MXPA01013354A (https=)
NO (1) NO331256B1 (https=)
NZ (1) NZ516594A (https=)
PL (1) PL201782B1 (https=)
PT (1) PT1194125E (https=)
SK (1) SK287322B6 (https=)
TR (1) TR200200013T2 (https=)
WO (1) WO2001003672A1 (https=)
ZA (1) ZA200200344B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009675A1 (en) * 2000-08-02 2002-02-07 Pfizer Limited Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
FR2834212A1 (fr) * 2001-12-27 2003-07-04 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
WO2004009085A3 (en) * 2002-07-19 2004-05-13 Ranbaxy Lab Ltd Taste masked sumatriptan tablets and processes for their preparation
WO2004066925A2 (en) 2003-01-24 2004-08-12 R.P. Scherer Technologies, Inc. Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
WO2004070017A3 (en) * 2003-02-04 2005-01-27 Bennes Inc Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
WO2004110492A3 (en) * 2003-06-06 2005-02-24 Glaxo Group Ltd Composition comprising triptans and nsaids
WO2008136636A1 (en) * 2007-05-08 2008-11-13 Industry-Academic Cooperation Foundation Chosun University Composition for fast disintegrating tablet containing herbal extract and its preparation method
WO2008128775A3 (en) * 2007-04-23 2009-04-23 Ratiopharm Gmbh Stabilised pharmaceutical composition containing pregabaline

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ATE346590T1 (de) * 2001-07-26 2006-12-15 Ethypharm Sa Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2002368090A1 (en) * 2002-07-17 2004-02-09 Eurand Pharmaceuticals Ltd Process for the preparation of pharmaceutical microcapsules with enhanced tastemasking and high dissolution rate
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
JP2007501810A (ja) * 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
PE20070698A1 (es) 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP5405752B2 (ja) * 2007-01-31 2014-02-05 大日本住友製薬株式会社 被覆された薬物含有粒子および該粒子を含む固形製剤
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
JPWO2010018614A1 (ja) * 2008-08-11 2012-01-26 味の素株式会社 呈味性が改善された親水性アミノ酸含有製剤
FR2935084B1 (fr) * 2008-08-19 2011-05-06 Pancosma Sa Pour L Ind Des Produits Biochimiques Additif pour l'alimentation animale et son procede de preparation
KR101069118B1 (ko) 2008-10-22 2011-09-30 경상대학교산학협력단 장용해성 염화콜린의 제조방법 및 이의 방법에 따라 제조되는 염화콜린
CN101879141B (zh) * 2009-05-05 2013-07-17 烟台绿叶动物保健品有限公司 一种掩味替米考星胃溶颗粒制剂
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
EP2316433A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of flurbiprofen
IN2012DN03377A (https=) * 2009-10-26 2015-10-23 Merck Sharp & Dohme
US8367104B2 (en) * 2009-10-28 2013-02-05 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
TR200909613A1 (tr) * 2009-12-22 2011-07-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Pregabalinin farmasötik bileşimleri.
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
AU2011274845B2 (en) * 2010-07-09 2015-07-30 Teijin Limited Orally disintegrating tablet
JP4803686B2 (ja) * 2010-08-31 2011-10-26 協和発酵キリン株式会社 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
KR101481772B1 (ko) * 2012-06-19 2015-01-14 주식회사 아리바이오 추출물을 고농도로 함유하는 과립 또는 환의 제조방법
CN102908337B (zh) * 2012-10-12 2014-03-05 大连医诺生物有限公司 微囊化氨基酸组合物及其制备方法
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
WO2015130760A1 (en) 2014-02-25 2015-09-03 Orbis Biosciences, Inc. Taste masking drug formulations
US10213437B2 (en) 2014-05-08 2019-02-26 Ctc Bio, Inc. Pharmaceutical preparation for masked taste oral administration, containing clomipramine
WO2015170939A1 (ko) * 2014-05-08 2015-11-12 주식회사 씨티씨바이오 클로미프라민 함유 맛 차폐된 구강 투여용 약학 제제
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
FR3078630B1 (fr) 2018-03-08 2021-05-14 Karim Ioualalen Mode de formulation sous forme de solide divise hydrophobe
JP2020105173A (ja) * 2018-12-27 2020-07-09 日本ケミファ株式会社 ２種以上の薬物を含有する口腔内崩壊錠及びその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525389A2 (de) * 1991-07-04 1993-02-03 Merz & Co. GmbH & Co. Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
WO1999009958A1 (en) * 1997-08-22 1999-03-04 Smithkline Beecham Corporation Rapidly disintegrating methylcellulose tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
JPS62126122A (ja) 1985-11-27 1987-06-08 Showa Shinyaku Kk 表面コ−テイングされたイブプロフエン顆粒の製法
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JPH0780754B2 (ja) 1986-08-06 1995-08-30 エーザイ株式会社 多顆粒型持続性錠剤
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
FR2679451B1 (fr) * 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
TW271400B (https=) * 1992-07-30 1996-03-01 Pfizer
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
AUPO637197A0 (en) 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
PL334439A1 (en) * 1997-01-06 2000-02-28 Pfizer Rapidly liberating and taste masking pharmaceutical administration form
CA2315088A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
FR2785539B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
EP0525389A2 (de) * 1991-07-04 1993-02-03 Merz & Co. GmbH & Co. Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
WO1999009958A1 (en) * 1997-08-22 1999-03-04 Smithkline Beecham Corporation Rapidly disintegrating methylcellulose tablets

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009675A1 (en) * 2000-08-02 2002-02-07 Pfizer Limited Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
FR2834212A1 (fr) * 2001-12-27 2003-07-04 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
WO2003055464A1 (fr) * 2001-12-27 2003-07-10 Besins International Belgique Poudre micronisee pharmaceutique ou nutraceutique a liberation immediate.
WO2004009085A3 (en) * 2002-07-19 2004-05-13 Ranbaxy Lab Ltd Taste masked sumatriptan tablets and processes for their preparation
WO2004066925A2 (en) 2003-01-24 2004-08-12 R.P. Scherer Technologies, Inc. Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
WO2004070017A3 (en) * 2003-02-04 2005-01-27 Bennes Inc Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US8236348B2 (en) 2003-02-04 2012-08-07 Bennes, Inc. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
WO2004110492A3 (en) * 2003-06-06 2005-02-24 Glaxo Group Ltd Composition comprising triptans and nsaids
WO2008128775A3 (en) * 2007-04-23 2009-04-23 Ratiopharm Gmbh Stabilised pharmaceutical composition containing pregabaline
WO2008136636A1 (en) * 2007-05-08 2008-11-13 Industry-Academic Cooperation Foundation Chosun University Composition for fast disintegrating tablet containing herbal extract and its preparation method

Also Published As

Publication number Publication date
DE60034565D1 (de) 2007-06-06
NO20016308D0 (no) 2001-12-21
CZ200218A3 (cs) 2002-04-17
HU229568B1 (hu) 2014-02-28
CA2375600A1 (fr) 2001-01-18
JP2003504324A (ja) 2003-02-04
SK19392001A3 (sk) 2002-04-04
BG65615B1 (bg) 2009-03-31
DK1194125T3 (da) 2007-07-30
HUP0202062A2 (hu) 2002-12-28
NO331256B1 (no) 2011-11-07
BR0012250A (pt) 2002-03-26
ES2284507T3 (es) 2007-11-16
FR2795962A1 (fr) 2001-01-12
PL354257A1 (en) 2003-12-29
CN1373658A (zh) 2002-10-09
PT1194125E (pt) 2007-07-03
SK287322B6 (sk) 2010-07-07
DZ3257A1 (fr) 2001-01-18
EA200200136A1 (ru) 2002-06-27
BG106398A (en) 2002-09-30
DE60034565T2 (de) 2007-12-27
IL147212A (en) 2007-05-15
CY1107695T1 (el) 2013-04-18
MXPA01013354A (es) 2002-07-09
HK1049119B (zh) 2006-05-12
CZ300154B6 (cs) 2009-02-25
HK1049119A1 (en) 2003-05-02
KR20020015062A (ko) 2002-02-27
US6660382B2 (en) 2003-12-09
MA25426A1 (fr) 2002-04-01
AU760006B2 (en) 2003-05-08
EP1194125A1 (fr) 2002-04-10
PL201782B1 (pl) 2009-05-29
US20020098227A1 (en) 2002-07-25
KR100767928B1 (ko) 2007-10-17
NZ516594A (en) 2003-11-28
EA003161B1 (ru) 2003-02-27
FR2795962B1 (fr) 2003-05-09
CN1220485C (zh) 2005-09-28
AU5993600A (en) 2001-01-30
JP4749639B2 (ja) 2011-08-17
IL147212A0 (en) 2002-08-14
CA2375600C (fr) 2011-05-10
NO20016308L (no) 2001-12-21
ATE360412T1 (de) 2007-05-15
TR200200013T2 (tr) 2002-06-21
ZA200200344B (en) 2003-03-26
HUP0202062A3 (en) 2004-05-28
EP1194125B1 (fr) 2007-04-25

Similar Documents

Publication Publication Date Title
EP1194125B1 (fr) Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
EP1496869B1 (fr) Particules enrobees a liberation prolongee et comprimes les contenant
JP3403203B2 (ja) ダリフェナシン含有製剤
CA2446781C (fr) Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'angiotensine
EP1100467A1 (fr) Procede de fabrication de particules de gabapentine ou de pregabaline enrobees
CA2428782C (fr) Medicament a base de microcapsules d'anti-hyperglycemiant a liberation prolongee et son procede de preparation
EP1003484A1 (fr) Comprime multiparticulaire perfectionne a delitement rapide
EP2276474B1 (fr) Forme orale solide dotee d'un double profil de liberation comprenant des multiparticules
FR2850576A1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
EP1333812B1 (fr) Microgranules a base de principe actif et leur procede de fabrication
WO2008113901A2 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
FR2850577A1 (fr) Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
JP4439499B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
EP1928408B1 (fr) Comprimes orodispersibles de principes actifs amers
JP5241681B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
EP1850835A1 (fr) Forme pharmaceutique orale de losartan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2375600

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000946045

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013354

Country of ref document: MX

Ref document number: IN/PCT/2001/01181/DE

Country of ref document: IN

Ref document number: DZP2001000845

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020017016695

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 19392001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2002-18

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 10041389

Country of ref document: US

Ref document number: 2002/00013

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 59936/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 516594

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/00344

Country of ref document: ZA

Ref document number: 200200344

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200200136

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2000 106398

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017016695

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008125880

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000946045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-18

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 59936/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 516594

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516594

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020017016695

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000946045

Country of ref document: EP